Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Cytek Biosciences (CTKB) Equity Average (2021 - 2025)

Historic Equity Average for Cytek Biosciences (CTKB) over the last 5 years, with Q3 2025 value amounting to $378.1 million.

  • Cytek Biosciences' Equity Average fell 238.3% to $378.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $378.1 million, marking a year-over-year decrease of 238.3%. This contributed to the annual value of $394.4 million for FY2024, which is 364.14% down from last year.
  • Latest data reveals that Cytek Biosciences reported Equity Average of $378.1 million as of Q3 2025, which was down 238.3% from $378.6 million recorded in Q2 2025.
  • In the past 5 years, Cytek Biosciences' Equity Average registered a high of $424.5 million during Q1 2023, and its lowest value of $196.1 million during Q3 2021.
  • Moreover, its 5-year median value for Equity Average was $404.3 million (2021), whereas its average is $390.0 million.
  • Per our database at Business Quant, Cytek Biosciences' Equity Average skyrocketed by 11101.91% in 2022 and then crashed by 777.48% in 2024.
  • Cytek Biosciences' Equity Average (Quarter) stood at $404.3 million in 2021, then rose by 4.14% to $421.0 million in 2022, then decreased by 3.97% to $404.3 million in 2023, then dropped by 3.39% to $390.6 million in 2024, then dropped by 3.21% to $378.1 million in 2025.
  • Its last three reported values are $378.1 million in Q3 2025, $378.6 million for Q2 2025, and $387.7 million during Q1 2025.